Evidence map›Paper›PMID 37415223›Full record

ArticleCritical care (London, England)2023

Plasma protein biomarkers reflective of the host response in patients developing Intensive Care Unit-acquired pneumonia.

Tjitske S R van Engelen, Tom D Y Reijnders, Fleur P Paling, Marc J M Bonten, Leen Timbermont, Surbhi Malhotra-Kumar, Jan A J W Kluytmans, Hessel Peters-Sengers, Tom van der Poll, ASPIRE-I. C. U. Study Team

Erratum issued Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Critical care (London, England), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT02413242 (Advanced Understanding of Staphylococcus Aureus and Pseudomonas Aeruginosa Infections in EuRopE - ICU), which is not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02413242 completednot on this map

Advanced Understanding of Staphylococcus Aureus and Pseudomonas Aeruginosa Infections in EuRopE - ICU

TypeobservationalSponsorJan KluytmansRan2015 to 2019Enrolled2,031ConditionsPneumonia, Pneumonia, Ventilator-Associated, Nosocomial PneumoniaArmsVarious observed exposure(s) of interest
3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Tjitske S R van EngelenCenter for Experimental and Molecular Medicine (CEMM), Amsterdam University Medical Centers, Location AMC, University of Amsterdam, Room G2-105, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands. t.s.vanengelen@amsterdamumc.nl.ORCID 0000-0001-6186-2550
Tom D Y ReijndersCenter for Experimental and Molecular Medicine (CEMM), Amsterdam University Medical Centers, Location AMC, University of Amsterdam, Room G2-105, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands.ORCID 0000-0002-1764-0114
Fleur P PalingJulius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.ORCID 0000-0002-5713-7652
Marc J M BontenJulius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.ORCID 0000-0002-9095-9201
Leen TimbermontLaboratory of Medical Microbiology, Vaccine and Infectious Disease Institute, University of Antwerp, Antwerp, Belgium.ORCID 0000-0002-9543-9205
Surbhi Malhotra-KumarLaboratory of Medical Microbiology, Vaccine and Infectious Disease Institute, University of Antwerp, Antwerp, Belgium.ORCID 0000-0001-8699-8905
Jan A J W KluytmansDepartment of Medical Microbiology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.ORCID 0000-0003-2665-6844
Hessel Peters-SengersCenter for Experimental and Molecular Medicine (CEMM), Amsterdam University Medical Centers, Location AMC, University of Amsterdam, Room G2-105, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands.ORCID 0000-0003-3145-864X
Tom van der PollCenter for Experimental and Molecular Medicine (CEMM), Amsterdam University Medical Centers, Location AMC, University of Amsterdam, Room G2-105, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands. t.vanderpoll@amsterdamumc.nl.ORCID 0000-0002-9199-5079
ASPIRE-I. C. U. Study Team
Amsterdam University Medical Centers · NLUniversity of Antwerp · BEUtrecht University · NL

Funding

Innovative Medicines Initiative Joint Undertakings 115523Innovative Medicines Initiative Joint Undertakings 115620Innovative Medicines Initiative Joint Undertakings 115737
6 · The paper itself

Abstract

backgroundImmune suppression has been implicated in the occurrence of pneumonia in critically ill patients. We tested the hypothesis that Intensive Care Unit (ICU)-acquired pneumonia is associated with broad host immune aberrations in the trajectory to pneumonia, encompassing inflammatory, endothelial and coagulation responses. We compared plasma protein biomarkers reflecting the systemic host response in critically ill patients who acquire a new pneumonia (cases) with those who do not (controls).

methodsWe performed a nested case-control study in patients undergoing mechanical ventilation at ICU admission with an expected stay of at least 48 h enrolled in 30 hospitals in 11 European countries. Nineteen host response biomarkers reflective of key pathophysiological domains were measured in plasma obtained on study inclusion and day 7, and-in cases-on the day of pneumonia diagnosis.

resultsOf 1997 patients, 316 developed pneumonia (15.8%) and 1681 did not (84.2%). Plasma protein biomarker analyses, performed in cases and a randomly selected subgroup of controls (1:2 ratio to cases, n = 632), demonstrated considerable variation across time points and patient groups. Yet, cases showed biomarker concentrations suggestive of enhanced inflammation and a more disturbed endothelial barrier function, both at study enrollment (median 2 days after ICU admission) and in the path to pneumonia diagnosis (median 5 days after ICU admission). Baseline host response biomarker aberrations were most profound in patients who developed pneumonia either shortly (< 5 days, n = 105) or late (> 10 days, n = 68) after ICU admission.

conclusionsCritically ill patients who develop an ICU-acquired pneumonia, compared with those who do not, display alterations in plasma protein biomarker concentrations indicative of stronger proinflammatory, procoagulant and (injurious) endothelial cell responses.

trial registrationClinicalTrials.gov Identifier: NCT02413242, posted April 9th, 2015.

Indexed as

Critical IllnessPneumoniaBiomarkersBlood ProteinsCase-Control StudiesHumansIntensive Care UnitsBiomarkersBlood ProteinsBiomarkersCritical careRespiratory tract infections

Identifiers

PMID37415223
PMCPMC10327365
OpenAlexW4383370865

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.